- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05976334
An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors
A Phase 1 Study to Assess Mass Balance, Pharmacokinetics, and Metabolism of [14C]Subasumstat in Patients With Advanced or Metastatic Solid Tumors
The main aim of this study is to assess how the human body of adults with advanced or metastatic solid tumors absorbs, distributes, metabolizes and excretes subasumstat following a single 1 hour infusion of subasumstat.
The study consists of two parts. In Part A, participants will receive a single infusion of C14 radiolabeled subasumstat. In Part B, participants will receive subasumstat treatment for up to 1 year.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The drug being tested in this study is called [14C]subasumstat. [14C]Subasumstat is being tested to assess mass balance and absorption, distribution, metabolism, excretion (ADME) of people who have advanced or metastatic solid tumors.
The study will enroll approximately 10 patients. Participants will be enrolled to receive a single dose of [14C]subasumstat:
- [14C]Subasumstat 90 mg
Participants will be administered with a single dose of [14C]subasumstat 90 mg as a 1-hour intravenous (IV) infusion on Day 1 of Part A. All participants will be monitored for up to 14 days postdose. Participants will then have an option to enter Part B of the study to receive non-radiolabelled subasumstat 90 mg, IV infusion on Days 1, 4, 8, and 11 of a 21-day cycle for 3 cycles up to maximum treatment duration of 1 year.
This multi-center trial will be conducted in Hungary. The overall study duration is 12 months for Part A and 24 months for Part B.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Takeda Contact
- Phone Number: +1-877-825-3327
- Email: medinfoUS@takeda.com
Study Locations
-
-
-
Budapest, Hungary, 1062
- Not yet recruiting
- Central Hospital of Northern Pest - Military Hospital
-
Principal Investigator:
- Zsuzsanna Pápai
-
Contact:
- Site Contact
- Phone Number: +36308281059
- Email: trial.zspapai@gmail.com
-
Budapest, Hungary, 1077
- Recruiting
- Pharmaceutical Research Associates Magyarorszag
-
Principal Investigator:
- Zsuzsanna Pápai
-
Contact:
- Site Contact
- Phone Number: +36308281059
- Email: trial.zspapai@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Participants have histologically or cytologically confirmed advanced (locally regionally recurrent not amenable to curative therapy) or metastatic solid tumors with no standard therapeutic option with a proven clinical benefit, are intolerant or have refused them.
- Participants have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group Performance Scale.
- Participants demonstrate adequate organ function.
- Participants have recovered to Grade 1 or baseline from all toxicity associated with previous therapy or have the toxicity established as sequela.
Key Exclusion Criteria:
- Participants received treatment with radioisotopes within 5 half-lives before the first dose of the study drug.
- Participants received radiolabelled substances, were exposed to radiation sources within 12 months of the first dose in this study, or is likely to receive radiation exposure or radioisotopes within 12 months of the first dose in this study such that participation in this study would increase their total exposure beyond the recommended safe levels.
- Participants received extended field radiotherapy ≤4 weeks before the start of treatment.
- Participants have uncontrolled brain metastasis. Participants with treated brain metastases are allowed provided they are radiologically stable, without evidence of progression for at least 4 weeks by repeat imaging, clinically stable, and without requirement of steroid treatment for at least 14 days before first dose of study treatment.
- Participants had a second malignancy within the previous 3 years, except treated basal cell or localized squamous skin carcinomas, prostate cancer, cervical carcinoma in situ, resected colorectal adenomatous polyps, breast cancer in situ, or other malignancy for which the patient is not on active anticancer therapies.
- Major surgery ≤14 days from the first dose of study drug and not recovered fully from any complications from surgery.
- Baseline prolongation of the QT interval when corrected using Fridericia's formula (QTcF).
- Receiving or requires the continued use of medications that are known to be strong or moderate inhibitors and inducers of cytochrome P450 (CYP) 3A4/5 and strong P-glycoprotein (Pgp) inhibitors.
- Has active noninfectious pneumonitis or interstitial lung disease that required steroids.
- History of allogeneic tissue or solid organ transplant.
- Participants have active bacterial infection requiring systemic therapy <14 days before the start of treatment.
- Participants have an active HIV or any other relevant congenital or acquired immunodeficiency.
- Active hepatitis B, or hepatitis C infection.
- Any of the following uncontrolled heart diseases: congestive heart failure New York Heart Association Grade III or IV, unstable angina, myocardial infarction, unstable symptomatic ischemic heart disease, uncontrolled hypertension despite appropriate medical therapy, ongoing symptomatic cardiac arrhythmias >Grade 2, pulmonary embolism or symptomatic cerebrovascular events, or any other serious cardiac condition (eg, pericardial effusion or restrictive cardiomyopathy). Chronic atrial fibrillation on stable anticoagulant therapy is allowed.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: [14C] Subasumstat 90 mg
Participants will receive a single dose of [14C] Subasumstat 90 mg, IV infusion on Day 1 in Part A of the study.
Following Part A, participants will have an option to receive subasumstat 90 mg, IV infusion on Days 1, 4, 8, and 11 of a 21 day cycle for 3 cycles followed by weekly maintenance dosing in Part B of the study up to maximum treatment duration of 1 year.
|
[14C] Subasumstat IV infusion.
Other Names:
Subasumstat IV infusion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cumulative Percentage of Urinary Recovery
Time Frame: Up to 14 days postdose
|
Cumulative amount of [14C]-radioactivity excreted in urine up to the last sampling interval.
|
Up to 14 days postdose
|
Cumulative Percentage of Fecal Recovery
Time Frame: Up to 14 days postdose
|
Cumulative amount of [14C]-radioactivity excreted in feces up to the last sampling interval.
|
Up to 14 days postdose
|
Cumulative Percentage of Combined Recovery
Time Frame: Up to 14 days postdose
|
Cumulative amount of [14C]-radioactivity excreted in urine, and feces up to the last sampling interval.
|
Up to 14 days postdose
|
Percentage Of Recovered Total Radioactivity (TRA) In Urine And Feces
Time Frame: Up to 14 days postdose
|
Percentage of recovered TRA in urine and feces for each interval over the entire period of collection will be reported.
|
Up to 14 days postdose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax: Maximum Observed Plasma Concentration for Subasumstat and TRA in Plasma and Whole Blood
Time Frame: Predose on Day 1 and at multiple time points postdose up to Day 14
|
Predose on Day 1 and at multiple time points postdose up to Day 14
|
|
Tmax: Time of First Occurrence of Cmax for Subasumstat and TRA in Plasma and Whole Blood
Time Frame: Predose on Day 1 and at multiple time points postdose up to Day 14
|
Predose on Day 1 and at multiple time points postdose up to Day 14
|
|
AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Subasumstat and TRA in Plasma and Whole Blood
Time Frame: Predose on Day 1 and at multiple time points postdose up to Day 14
|
Predose on Day 1 and at multiple time points postdose up to Day 14
|
|
Terminal Disposition Phase Half-life (T1/2z) for Subasumstat and TRA in Plasma and Whole Blood as Permitted by Data
Time Frame: Predose on Day 1 and at multiple time points postdose up to Day 14
|
Predose on Day 1 and at multiple time points postdose up to Day 14
|
|
Clearance (CL) for Subasumstat and TRA in Plasma and Whole Blood as Permitted by Data
Time Frame: Predose on Day 1 and at multiple time postdose points up to Day 14
|
Predose on Day 1 and at multiple time postdose points up to Day 14
|
|
Volume of Distribution at Steady-state (Vss) for Subasumstat and TRA in Plasma and Whole Blood as Permitted by Data
Time Frame: Predose on Day 1 and at multiple time points postdose up to Day 14
|
Predose on Day 1 and at multiple time points postdose up to Day 14
|
|
AUC∞: Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for Subasumstat and TRA in Plasma and Whole Blood as Permitted by Data
Time Frame: Predose on Day 1 and at multiple time points postdose up to Day 14
|
Predose on Day 1 and at multiple time points postdose up to Day 14
|
|
Cumulative Amount of Unchanged Subasumstat and TRA Excreted into the Urine (Aeurine)
Time Frame: Predose on Day 1 and at multiple time points postdose up to Day 14
|
Predose on Day 1 and at multiple time points postdose up to Day 14
|
|
Renal Clearance (CLR) for Subasumstat and TRA in Urine
Time Frame: Predose on Day 1 and at multiple time points postdose up to Day 14
|
Predose on Day 1 and at multiple time points postdose up to Day 14
|
|
Number of Participants With One or More Adverse Events (AEs)
Time Frame: From the start of study drug administration through 30 days after the last dose of study drug (up to approximately 1 year)
|
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
|
From the start of study drug administration through 30 days after the last dose of study drug (up to approximately 1 year)
|
Number of Participants With One or More Serious Adverse Events (SAEs)
Time Frame: From the start of study drug administration through 30 days after the last dose of study drug (up to approximately 1 year)
|
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
A SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event.
|
From the start of study drug administration through 30 days after the last dose of study drug (up to approximately 1 year)
|
Number of Participants With Abnormal Electrocardiogram Findings
Time Frame: From the start of study drug administration through the last dose of study drug (up to approximately 1 year)
|
Abnormal laboratory values are those outside of normal range as assessed by the investigator.
|
From the start of study drug administration through the last dose of study drug (up to approximately 1 year)
|
Number of Participants With Abnormal Laboratory Values
Time Frame: From the start of study drug administration through the last dose of study drug (up to approximately 1 year)
|
Laboratory findings will include serum chemistry, hematology and urinalysis.
Abnormal laboratory values are those outside of normal range as assessed by the investigator.
|
From the start of study drug administration through the last dose of study drug (up to approximately 1 year)
|
Relative Percentage of Circulatory Metabolites in Plasma
Time Frame: Predose on Day 1 and at multiple time points postdose up to Day 14
|
Predose on Day 1 and at multiple time points postdose up to Day 14
|
|
Relative Percentage Excretory Metabolites in Urine
Time Frame: Predose on Day 1 and at multiple time points postdose up to Day 14
|
Predose on Day 1 and at multiple time points postdose up to Day 14
|
|
Relative Percentage Excretory Metabolites in Feces
Time Frame: Predose on Day 1 and at multiple time points postdose up to Day 14
|
Predose on Day 1 and at multiple time points postdose up to Day 14
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Study Director, Takeda
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TAK-981-1004
- 2023-503449-79 (Other Identifier: EU CTIS)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumors
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
National Cancer Institute (NCI)RecruitingSolid Tumor | Refractory Solid Tumors | Malignant Solid Tumors | Other Neoplasms Solid Tumors | Pediatric Solid TumorUnited States
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
-
Esperance Pharmaceuticals IncCompletedAdvanced Solid Tumors | Solid TumorsUnited States
-
Incyte Biosciences Japan GKCompletedAdvanced Solid Tumors | Metastatic Solid TumorsJapan
-
Memorial Sloan Kettering Cancer CenterKyowa Hakko Kirin Pharma, Inc.CompletedAdvanced Solid Tumors | Metastatic Solid TumorsUnited States
-
Bristol-Myers SquibbCompletedAdvanced Solid Tumors | Metastatic Solid TumorsKorea, Republic of, Canada, Australia
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Alphamab (Australia) Co Pty Ltd.RecruitingAdvanced Solid Tumors | Metastatic Solid TumorsAustralia
Clinical Trials on [14C] Subasumstat
-
Indivior Inc.CompletedOpioid Use DisorderUnited States
-
Arcus Biosciences, Inc.Gilead SciencesCompleted
-
BiogenDenali Therapeutics Inc.Completed
-
Denovo Biopharma LLCCompleted
-
Athira PharmaAlturas Analytics, Inc.; Labcorp Drug Development IncCompletedHealthy VolunteersUnited States
-
Laekna LimitedCompleted
-
Reata, a wholly owned subsidiary of BiogenCompleted
-
Cyclerion TherapeuticsCompletedHealthy VolunteersUnited States
-
PfizerArvinas Estrogen Receptor, Inc.Completed
-
BiogenDenali Therapeutics Inc.CompletedHealthy VolunteersUnited States